<?xml version="1.0" encoding="iso-8859-1" ?>
<newsitem itemid="477979" id="root" date="1997-04-01" xml:lang="en">
<title>USA: Titan Pharmaceuticals Q4 shr loss $0.32.</title>
<headline>Titan Pharmaceuticals Q4 shr loss $0.32.</headline>
<dateline>SOUTH SAN FRANCISCO, Calif. 1997-04-01</dateline>
<text>
<p>TITAN PHARMACEUTICALS, INC.</p>
<p>			   (a development stage company)</p>
<p>	     CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</p>
<p>				    (Unaudited)</p>
<p>					Three Months Ended December 31,</p>
<p>							 1995	   1996</p>
<p> Grant revenue				 $  39,736    $ 125,750</p>
<p>Costs and expenses:</p>
<p>    Research and development		 799,329    1,542,936</p>
<p>Acquired in-process research &amp; development</p>
<p>						     686,000	    ---</p>
<p>    General and administrative	     121,825    2,381,249</p>
<p> Total costs and expenses		  1,607,154    3,924,185</p>
<p> Loss from operations		    (1,567,418)  (3,798,435)</p>
<p>Other income (expense):</p>
<p>Equity in loss of Ansan Pharmaceuticals, Inc.</p>
<p>						   (223,346)    (299,135)</p>
<p>    Interest income			     21,978	197,416</p>
<p>    Interest expense		     (1,072,147)     (67,318)</p>
<p>	 Other income (expense) - net  (1,273,515)    (169,037)</p>
<p>  Loss before minority interest	(2,840,933)  (3,967,472)</p>
<p>Minority interest in losses of subsidiaries</p>
<p>							   825	    ---</p>
<p>	 Net loss			    (2,840,108)  (3,967,472)</p>
<p> Proforma net loss per share		  (0.36)</p>
<p>Shares used in computing proforma net</p>
<p>	 loss per share			7,889,189</p>
<p> Net loss per share						(0.32)</p>
<p>Shares used in computing net loss per share</p>
<p>								   12,369,349</p>
<p>			     TITAN PHARMACEUTICALS, INC.</p>
<p>			    (a development stage company)</p>
<p>			CONSOLIDATED STATEMENTS OF OPERATIONS</p>
<p>			  Year Ended December 31,	 Period from</p>
<p>				     1995	   1996   Commencement</p>
<p>								Of Operations</p>
<p>							 (July 25, 1991) to</p>
<p>							  December 31, 1996</p>
<p> Grant revenue	   $  139,522    $  258,811    $  398,333</p>
<p>Costs and expenses:</p>
<p>Research and development</p>
<p>				5,201,507     5,566,772    27,580,393</p>
<p>Acquired in-process</p>
<p>research &amp; development</p>
<p>				  686,000	     ---	 686,000</p>
<p>General and administrative</p>
<p>				3,657,900     5,263,964    11,828,346</p>
<p>Total costs and expenses</p>
<p>				9,545,407    10,830,736    40,094,739</p>
<p>Loss from operations</p>
<p>			    (9,405,885)  (10,571,925)  (39,696,406)</p>
<p>Other income (expense):</p>
<p>Equity in loss of Ansan</p>
<p>Pharmaceuticals, Inc.</p>
<p>				(457,114)     (998,972)   (1,456,086)</p>
<p>    Interest income	  67,868	 715,984     1,170,742</p>
<p>    Interest expense  (1,899,148)   (2,010,664)   (4,163,002)</p>
<p>Other expense - net</p>
<p>			    (2,288,394)   (2,293,652)   (4,448,346)</p>
<p>Loss before minority</p>
<p>     interest	  (11,694,279)  (12,865,577)  (44,144,752)</p>
<p>Minority interest in losses</p>
<p>  of subsidiaries		 825	   9,931	  44,850</p>
<p>    Net loss	   (11,693,454)  (12,855,646)  (44,099,902)</p>
<p>Proforma net loss per share (1.54)</p>
<p>Shares used in computing</p>
<p>  proforma net loss per share   7,617,470</p>
<p> Net loss per share			    (1.67)</p>
<p>Shares used in computing net</p>
<p>  loss per share			   10,936,046</p>
</text>
<copyright>(c) Reuters Limited 1997</copyright>
<metadata>
<codes class="bip:countries:1.0">
  <code code="USA">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1997-04-01"/>
  </code>
</codes>
<codes class="bip:industries:1.0">
  <code code="I25000">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1997-04-01"/>
  </code>
</codes>
<codes class="bip:topics:1.0">
  <code code="C15">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1997-04-01"/>
  </code>
  <code code="C151">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1997-04-01"/>
  </code>
  <code code="C1511">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1997-04-01"/>
  </code>
  <code code="CCAT">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1997-04-01"/>
  </code>
</codes>
<dc element="dc.date.created" value="1997-04-01"/>
<dc element="dc.publisher" value="Reuters Holdings Plc"/>
<dc element="dc.date.published" value="1997-04-01"/>
<dc element="dc.source" value="Reuters"/>
<dc element="dc.creator.location" value="SOUTH SAN FRANCISCO, Calif."/>
<dc element="dc.creator.location.country.name" value="USA"/>
<dc element="dc.source" value="Reuters"/>
</metadata>
</newsitem>
